Investment Rating - The report maintains an "Overweight" rating for the non-bank financial sector [1] Core Insights - The insurance sector continues to show high growth despite a high base in Q3, driven by regulatory support for high-quality health insurance development [5][22] - The securities sector has seen a year-on-year increase in trading volume, with significant growth in margin financing balances [5][15] - The multi-financial sector is transitioning into a stable growth phase, with trust assets increasing but profits declining significantly [5][32] Summary by Sections Non-Bank Financial Subsector Performance - In the recent five trading days (October 13-17, 2025), only the insurance sector outperformed the CSI 300 index, rising by 3.73%, while the overall non-bank financial sector declined by 1.09% [10][11] Non-Bank Financial Subsector Views Securities - Trading volume has increased year-on-year, with the average daily trading amount in October reaching 27,366 billion yuan, up 22.33% from the previous year [5][15] - The China Securities Regulatory Commission has revised the corporate governance guidelines for listed companies, enhancing oversight and accountability [17][20] Insurance - Major insurers like New China Life and China Property & Casualty are expected to report significant profit increases for Q3, with New China Life's net profit projected between 30 billion to 34.1 billion yuan, a year-on-year growth of 45% to 65% [5][22] - Regulatory initiatives are promoting the development of health insurance, with a focus on integrating new medical technologies and improving long-term care insurance [26][30] Multi-Financial - The trust industry is experiencing a stable transition, with total trust assets reaching 29.56 trillion yuan by the end of 2024, but profits have dropped significantly [5][32] - The futures market saw a year-on-year increase in transaction volume and value, indicating a potential recovery in trading activity [5][37] Industry Ranking and Key Company Recommendations - The report ranks the sectors as follows: Insurance > Securities > Other Multi-Financial [5][47] - Key company recommendations include China Ping An, New China Life, China Pacific Insurance, CITIC Securities, Tonghuashun, and Jiufang Zhitu Holdings, highlighting the low average valuations and safety margins in the non-bank financial sector [5][47]

Core Viewpoint - The recent guidance from the Financial Regulatory Bureau aims to enhance the quality and sustainability of health insurance, addressing the evolving needs of the population for diverse health protection [1][9]. Summary by Sections Health Insurance Market Dynamics - The health insurance sector is experiencing increased demand due to economic development and the "Healthy China" strategy, but it faces challenges such as product homogeneity and insufficient operational capabilities [1]. - In 2024, the top five health insurance companies in China are projected to hold a market share of 62%, with over 70% product overlap, leading to a price war that pressures industry profit margins [1]. Regulatory Changes and Product Innovation - The guidance emphasizes the development of four main types of health insurance: commercial medical insurance, long-term care insurance, income loss insurance due to disability, and disease insurance [2]. - The reintroduction of participating long-term health insurance, after 22 years, signals a regulatory push towards normalizing floating yield products in the health insurance sector [2][3]. Commercial Medical Insurance - The guidance promotes the active development of commercial medical insurance, aiming to create a comprehensive and multi-tiered product system that includes new medical technologies and treatments [5][12]. - The introduction of personal account-based long-term medical insurance is highlighted, which allows individuals to accumulate funds for out-of-pocket medical expenses, addressing the issue of underutilized medical insurance balances [5][6]. Integration of Health Management - The guidance calls for the integration of health insurance with health management, reflecting a shift in consumer demand from reactive treatment to proactive health management [7]. - Data indicates that clients participating in health management services experience an 18% reduction in major disease incidence and a 22% decrease in hospitalization costs, underscoring the importance of health management in controlling insurance payouts [7]. Industry Trends and Future Outlook - Leading insurance companies are already investing in health management ecosystems, with initiatives to combine insurance with health services [8]. - The implementation of the guidance is expected to enhance the role of health insurance in the overall health protection system by 2030, promoting a multi-layered market that meets diverse needs [11].

Core Viewpoint - The recent rise in domestic insurance stocks is attributed to the issuance of guidelines by the Financial Regulatory Bureau aimed at promoting the high-quality development of health insurance, which includes the reintroduction of participating long-term health insurance products after a 22-year hiatus [1] Group 1: Stock Performance - Domestic insurance stocks collectively rose, with notable increases: Xinhua Insurance up 3.11% to HKD 48.46, China Pacific Insurance up 3.02% to HKD 31.4, China Life Insurance up 3.02% to HKD 22.52, and Ping An Insurance up 1.03% to HKD 54.05 [1] Group 2: Regulatory Changes - The Financial Regulatory Bureau issued guidelines that outline the overall direction and phased goals for the development of health insurance, specifically supporting well-rated insurance companies in launching participating long-term health insurance products [1] Group 3: Market Implications - The reintroduction of participating health insurance is expected to enhance product attractiveness and stimulate growth potential in the health insurance market, especially in the context of continuously declining preset interest rates [1] - The guidelines are anticipated to enrich product offerings and improve the appeal of "product + service," potentially leading to a new wave of development opportunities for various health insurance types, while also reducing risk related to interest rate spreads for insurance companies, thereby benefiting profitability and valuation levels [1]

Core Viewpoint - The recent rise in Chinese insurance stocks is attributed to the release of regulatory guidelines aimed at promoting the high-quality development of health insurance, which includes the reintroduction of participating health insurance products after a 22-year hiatus [1][1][1] Group 1: Stock Performance - Chinese insurance stocks collectively experienced gains, with notable increases: Xinhua Insurance rose by 3.11% to HKD 48.46, China Pacific Insurance increased by 3.02% to HKD 31.4, China Life Insurance also rose by 3.02% to HKD 22.52, and Ping An Insurance saw a 1.03% increase to HKD 54.05 [1][1][1] Group 2: Regulatory Developments - The Financial Regulatory Bureau issued guidelines that outline the overall direction and phased goals for the development of health insurance, specifically supporting well-rated insurance companies in launching participating long-term health insurance products [1][1][1] - The reintroduction of participating health insurance products is expected to enhance product attractiveness and stimulate growth in the health insurance market [1][1][1] Group 3: Market Implications - Dongwu Securities noted that the return of participating health insurance products could help improve product appeal and further unlock the growth potential of the health insurance market, especially in the context of declining preset interest rates [1][1][1] - Kaiyuan Securities highlighted that the new guidelines are likely to enrich product offerings and enhance the attractiveness of "product + service" combinations, potentially leading to a new wave of development opportunities for various health insurance types, while also reducing risk related to interest rate spreads for insurance companies [1][1][1]

Investment Rating - The industry investment rating is maintained as "Add" [1] Core Viewpoints - The report suggests that with policy support, there is potential for innovation and upgrade in health insurance products, leading to a win-win collaboration between insurance and the health industry. Health insurance premiums totaled 759.8 billion yuan from January to August 2025, reflecting a year-on-year growth of 2.4%, accounting for approximately 20% of life insurance premiums [1][6][7] - The report emphasizes the return of participating health insurance products to the market, which is expected to enhance product attractiveness and stimulate market growth potential. The guidance from the regulatory body aims to deepen cooperation between insurance and health industries, promoting product innovation and improving the accessibility of innovative drugs and medical devices [1][5] - The report indicates improvements on both the liability and asset sides, with significant upward valuation potential remaining. The demand for savings in the market is still strong, and with ongoing regulatory guidance and proactive transformation by insurance companies, liability costs are expected to gradually decrease, alleviating pressure from interest rate spreads [1][5] - The report notes that the recent decline in the yield of ten-year government bonds to approximately 1.86% may ease the pressure on the investment returns of insurance companies in fixed-income investments as the domestic economy recovers [1][5] - The report highlights that the current valuation of the insurance sector is at historical lows, with estimates for September 30, 2025, indicating a price-to-earnings value (PEV) of 0.57-0.86 and a price-to-book ratio (PB) of 1.02-2.19, suggesting a favorable investment opportunity [1][5] Summary by Sections Industry Trends - The report outlines a clear goal for health insurance to play a more significant role in the national health security system by 2030, with a focus on developing a multi-level health insurance market that meets diverse needs across the population and lifecycle [5] - It discusses the need for reform in various segments, including commercial medical insurance, long-term care insurance, and disease insurance, to support the development of floating income health insurance products and enhance the sustainability of urban commercial medical insurance [5] Regulatory Guidance - The report mentions the issuance of guidelines by the National Financial Supervision Administration to promote high-quality development in health insurance, emphasizing the importance of regulatory oversight and risk prevention [5] - It highlights the need for insurance companies to enhance their operational capabilities and strengthen health insurance regulation to optimize the development environment [5]